Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone847-871-0377
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.96 million
Profitability
Miscellaneous
Employees64
OptionableNot Optionable
Aptinyx (NASDAQ:APTX) Frequently Asked Questions
What is Aptinyx's stock symbol?
Aptinyx trades on the NASDAQ under the ticker symbol "APTX."
How were Aptinyx's earnings last quarter?
Aptinyx Inc (NASDAQ:APTX) announced its earnings results on Tuesday, November, 13th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($1.01) by $0.58. The firm had revenue of $0.94 million for the quarter, compared to analyst estimates of $1.10 million. View Aptinyx's Earnings History.
When is Aptinyx's next earnings date?
What price target have analysts set for APTX?
5 analysts have issued 1 year target prices for Aptinyx's shares. Their predictions range from $8.00 to $40.00. On average, they expect Aptinyx's share price to reach $25.50 in the next twelve months. This suggests a possible upside of 373.1% from the stock's current price. View Analyst Price Targets for Aptinyx.
What is the consensus analysts' recommendation for Aptinyx?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptinyx.
Has Aptinyx been receiving favorable news coverage?
News coverage about APTX stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aptinyx earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
Who are some of Aptinyx's key competitors?
Some companies that are related to Aptinyx include Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Principia Biopharma (PRNB), Y-mAbs Therapeutics (YMAB), Epizyme (EPZM), CytomX Therapeutics (CTMX), AC Immune (ACIU), Dynavax Technologies (DVAX), Revance Therapeutics (RVNC), ImmunoGen (IMGN), Radius Health (RDUS), G1 Therapeutics (GTHX), Intra-Cellular Therapies (ITCI), Rocket Pharmaceuticals (RCKT) and Urogen Pharma (URGN).
Who are Aptinyx's key executives?
Aptinyx's management team includes the folowing people:
- Mr. Norbert G. Riedel, Pres, CEO & Director (Age 60)
- Dr. Joseph R. Moskal Ph.D., Chief Scientific Officer (Age 67)
- Dr. Torsten Meldgaard Madsen, Chief Medical Officer (Age 51)
- Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 42)
- Mr. Nicholas C. Smith, Director of Corp. Devel.
When did Aptinyx IPO?
(APTX) raised $77 million in an IPO on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.
When did the company's lock-up period expire?
Aptinyx's lock-up period expired on Tuesday, December 18th. Aptinyx had issued 6,399,999 shares in its IPO on June 21st. The total size of the offering was $102,399,984 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.
How do I buy shares of Aptinyx?
Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aptinyx's stock price today?
One share of APTX stock can currently be purchased for approximately $5.39.
How big of a company is Aptinyx?
Aptinyx has a market capitalization of $200.31 million and generates $4.96 million in revenue each year. Aptinyx employs 64 workers across the globe.
What is Aptinyx's official website?
How can I contact Aptinyx?
Aptinyx's mailing address is 1801 MAPLE AVENUE SUITE 4300, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]
MarketBeat Community Rating for Aptinyx (NASDAQ APTX)
MarketBeat's community ratings are surveys of what our community members think about Aptinyx and other stocks. Vote "Outperform" if you believe APTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
